These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). Tammaro KA; Baldwin PD; Lundberg AS J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601 [TBL] [Abstract][Full Text] [Related]
7. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer. Chang SC; Chang CY; Chang SJ; Yuan MK; Lai YC; Liu YC; Chen CY; Kuo LC; Yu CJ Clin Lung Cancer; 2013 Jan; 14(1):55-61. PubMed ID: 22607779 [TBL] [Abstract][Full Text] [Related]
8. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. Beom SH; Kim DW; Sim SH; Keam B; Park JH; Lee JO; Kim TM; Lee SH; Heo DS Cancer Res Treat; 2016 Jan; 48(1):88-97. PubMed ID: 25761482 [TBL] [Abstract][Full Text] [Related]
9. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease. Yuan MK; Chang CY; Chang SC; Chang SJ; Tang GJ; Wei YF; Liu YC; Chen CY; Yu CJ Int J Clin Pharmacol Ther; 2011 Oct; 49(10):587-93. PubMed ID: 21961483 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739 [TBL] [Abstract][Full Text] [Related]
11. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256 [TBL] [Abstract][Full Text] [Related]
12. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163 [TBL] [Abstract][Full Text] [Related]